Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in India / NCT06927102
Recruiting Observational

From Exclusion to Inclusion: Analysing Follow-up Discontinuity in Breast Cancer

NCT06927102 · tracked via the Priya Life Science India tracker
Sponsor
Basavatarakam Indo American Cancer Hospital & Research Institute
Phase
Observational
Started
2025-05-01
Last updated
2025-09-19

Condition(s) studied

Breast Carcinoma

Study summary

The goal of this observational study is to determine the proportion of patients who are lost-to-follow-up at five years, identify factors associated with loss of follow-up , and explore patient-reported barriers to follow-up in a public sector cancer care setting.

The main question it aims to answer is : Do proactive outreach programs help in improving follow-up rates among breast cancer patients who are categorized as "lost-to-follow-up." This study will be conducted in a real-world cohort of women with non-metastatic breast cancer treated at a tertiary care centre, between 2017-2018.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patients newly diagnosed with non-metastatic breast cancer between 2017-2018 2. Patients categorized as "lost-to-follow-up", as defined above 3. Patients willing to participate upon re-engagement Exclusion Criteria: 1. Patients with incomplete medical records 2. Patients who have taken part of the treatment at another hospital/centre 3. Patients who have relocated permanently out of the study region Withdrawal Criteria: 1\. Patient withdraws consent

Primary outcome measure(s)

  • Improvement in follow-up data with proactive outreach — 6 months
    Follow-up data will be retrieved from hospital records and electronic medical records (EMR) up to December 2024. For patients identified as lost-to-follow-up, proactive outreach efforts will be undertaken via phone calls, messages, or emails. Patients (or their families) will be queried about recurrence of disease, and these responses will be documented as valid follow-up entries.
  • Updated mortality data — 6 months
    For patients identified as lost-to-follow-up, proactive outreach efforts will be undertaken via phone calls, messages, or emails. Patients (or their families) will be queried about mortality (if applicable) and these responses will be documented as valid follow-up entries.

Trial sites (1)

FacilityCityRegionStatus
Basavatarakam Indo American Cancer Hospital & Research Institute Hyderabad Telangana Recruiting

More Basavatarakam Indo American Cancer Hospital & Research Institute trials in India

FLuorescent Angiography in REduction of Anastomotic Leak in Rectal Cancer Surgery Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06927102 on ClinicalTrials.gov ↗ ← All trials in India